Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
After 3 CRLs, FDA approves Outlook's AMD drug Lytenava
The FDA has approved Outlook's Lytenava for wet age-related macular degeneration. The compound has been used off-label in the indication for two decades.
Kevin Dunleavy
Jul 27, 2026 11:51am
Sarepta taps AbbVie vet Severino to take over for retiring CEO
Jul 27, 2026 11:36am
The CSO Model Is Endangered. Here’s How to Evolve.
Brought to you by
Mix Talent
AZ leans on cancer, rare disease muscle in solid Q2
Jul 27, 2026 10:21am
Advancing mCSPC Treatment: A Closer Look at ADT + Darolutamide with Dr. Rana McKay
Brought to you by
Bayer
Legend Biotech CEO resigns; search underway for replacement
Jul 27, 2026 9:32am
